Korean J Pathol.  2011 Aug;45(4):379-385.

Insulin-like Growth Factor II mRNA-Binding Protein 3 Expression in Benign and Premalignant Lesions and Carcinomas of the Stomach

Affiliations
  • 1Department of Pathology, Gyeongsang National University School of Medicine, Jinju, Korea. gyunghko@gnu.ac.kr
  • 2Gyeongsang Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea.
  • 3Department of Surgery, Gyeongsang National University School of Medicine, Jinju, Korea.

Abstract

BACKGROUND
Recent studies have demonstrated that insulin-like growth factor II mRNA-binding protein 3 (IMP3) is expressed in malignant tumors of various organs but not in normal tissue. We investigated IMP3 expression in various benign lesions, premalignant lesions and carcinomas of the stomach.
METHODS
IMP3 immunohistochemical staining was performed on 24 benign gastric lesions, 24 gastric adenomas, and 322 gastric carcinomas.
RESULTS
IMP3 was not expressed in benign gastric lesions including adenomas with low-grade dysplasia, but was expressed in 17% of adenomas with high-grade dysplasia, and in 44% of carcinomas. As the carcinomas were in the advanced stage, they expressed IMP3 more frequently and strongly. Patients with IMP3-positive tumors had poorer survival than those with negative tumors.
CONCLUSIONS
IMP3 expression in gastric carcinoma may be related to tumor invasion and metastasis, and is an independent risk factor for poor prognosis.

Keyword

Stomach; Carcinoma; Adenoma; IMP3 protein

MeSH Terms

Adenoma
Humans
Insulin-Like Growth Factor II
Neoplasm Metastasis
Prognosis
Risk Factors
Stomach
Insulin-Like Growth Factor II
Full Text Links
  • KJP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr